Complete Remission Of Recurrent Ovarian Clear Cell Carcinoma By Chemotherapy With Bevacizumab, Trabectedin And Oxaliplatin .
Article first published online: 20 NOV 2012 .
Masashi Takano , Yuji Ikeda , Kazuya Kudoh , Tsunekazu Kita , Naoki Sasaki , Yoshihiro Kikuchi .
Department of Obstetrics and Gynecology, National Defense Medical College; Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women.© 2012 The Authors. Journal of Obstetrics and Gynaecology Research © 2012 Japan Society of Obstetrics and Gynecology .
Abstract
Clear cell carcinoma of the ovary has shown an exceedingly chemo-resistant phenotype, especially in cases that are recurrent or refractory to previous therapy. Also, progression-free survival was less than 6 months, even in the patients that achieved response when they were treated with conventional anti-cancer cytotoxic agents. We present a case with recurrent and refractory ovarian clear cell carcinoma that achieved complete remission using a combination of bevacizumab, trabectedin and oxaliplatin. The progression-free interval of the patient is over 30 months, and she is still receiving the combination therapy without toxicities of more than grade 2.